Fresenius Medical Care ( ($FMS) ) has shared an announcement. On April 1, 2025, Fresenius Medical Care successfully placed bonds totaling €1.1 ...

Fresenius, Danone and Proximus benchmarks shake off tariff turmoil ◆ Range of new issue concessions needed ◆ High orderbook attrition for those pushing hard on spread ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss ...

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

The primary driver behind last 12 months revenue was the Fresenius Helios segment contributing a total revenue of €12.7b (58% ...

On March 26, 2025, the FDA approved Fresenius Kabi’s denosumab biosimilars, CONEXXENCE® (denosumab-bnht) and BOMYNTRA® (denosumab-bnht), ...

The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...

The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for ...

Fresenius said the U.S. Food and Drug Administration has approved a biologics license application for its operating company's bone-disease drugs. The approval concerns Fresenius Kabi's Conexxence and ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

In a report released today, Graham Doyle from UBS maintained a Buy rating on Fresenius SE & Co. KGaA (0OO9 – Research Report), with a price ...